In our comprehensive study, we conducted molecular modelling analyses to identify potential drug candidates for targeting four key proteins involved in lung cancer: CDK2, SRC-2 domains of C-ABL, EGFR, and IGF-1R kinase. This evidence concerns the gene SRC and lung cancer.